Answer
As a precaution, Cinqaero (reslizumab) should preferably be avoided during pregnancy because human pregnancy data are absent or limited, and its long half-life should be considered.
Sources for this answer
- Cinqaero (reslizumab) 10 mg/mL concentrate for solution for infusionTeva Pharmaceuticals Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 8Document updated
Sources checked